Neumirna Therapeutics
PrivateLast Round
Grant
Jun 12, 2025
Total Funding Raised
$23.13M
Company Overview
Neumirna Therapeutics is a biotechnology company that develops miRNA-based therapies targeting the root causes of neurological diseases such as epilepsy and Parkinson's.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neumirna Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Neumirna Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 12, 2025 | ||||
| Series A | Jan 8, 2025 | ||||
| Grant | Jun 12, 2024 | ||||
| Grant | Feb 29, 2024 | ||||
| Grant | Dec 15, 2023 | ||||
Grant | Aug 1, 2023 |
Neumirna Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovation Fund Denmark | Grant |
| Innovestor | Series A, Seed |
| CURE Epilepsy | Grant |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
| Angelini Ventures | Series A |
| Sunstone Life Science Ventures | Seed |
| Invivo Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 12, 2026
Presented RNA-based approach for drug-resistant epilepsy at AES Annual Meeting.
- Sep 17, 2025
Ellen K. Donnelly, Ph.D. appointed as new Chief Executive Officer.
Neumirna Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Neumirna Therapeutics's valuation, stock price, and market status.